Find Academic Supervisors

Jeffrey MorganView profile

Professor

• Tissue Engineering
• Biomedical Engineering
• 3D Microtissue Models
• +3 more

Jeffrey Morgan is a Professor of Medical Science and Engineering at Brown University's School of Engineering. His research focuses on biofabrication, 3D microtissue engineering, and extracellular matrix biology. He develops innovative systems for toxicity testing, cardiac regeneration, and organ-on-a-chip models. Key contributions include the design of non-adhesive hydrogels for self-assembling microtissues and advanced imaging techniques (e.g., OCT viability imaging). His work bridges engineering and medicine, addressing challenges in regenerative therapies and in vitro testing platforms. Research interests emphasize the synthesis and mechanical properties of extracellular matrices, cellular interactions in engineered tissues, and the application of bioengineering solutions to clinical problems such as myocardial infarction and liver toxicity. He has pioneered methods for scalable production of microtissues and their use in drug screening and tissue repair. His articles highlight advancements in collagen dynamics, bioactive material development, and the integration of imaging technologies with tissue engineering. Ongoing projects include refining 3D models for disease modeling and exploring ECM-based therapies for cardiac remodeling. The absence of listed awards suggests a focus on impactful technical contributions over accolades.

Donald E. IngberView profile

Professor

• Biologically Inspired Engineering
• Mechanobiology
• Vascular Biology
• +6 more

Donald E. Ingber, M.D., Ph.D. is the Founding Director of the Wyss Institute for Biologically Inspired Engineering at Harvard University, where he also holds the Judah Folkman Professorship of Vascular Biology at Harvard Medical School and Boston Children's Hospital, and the Hansjörg Wyss Professorship of Biologically Inspired Engineering at the Harvard John A. Paulson School of Engineering and Applied Sciences. A pioneer in biologically inspired engineering, he leads interdisciplinary teams developing breakthrough bioinspired technologies to advance healthcare and sustainability. Ingber's research spans multiple disciplines including mechanobiology, tissue engineering, tumor angiogenesis, systems biology, and nanobiotechnology. He is best known for discovering the role of mechanical forces in developmental control and cancer formation, and for applying these principles to develop innovative medical devices and therapeutics. His most notable contribution is the development of 'Organs-on-Chips' technology, which mimics human organ functions and has been recognized with numerous design awards including acquisition by the Museum of Modern Art for its permanent collection. His recent work shows continued innovation in microphysiological systems, with numerous 2025 publications focusing on human organ chip models for disease research, drug testing, and understanding fundamental biological processes. These studies demonstrate the maturation of organ chip technology into sophisticated platforms for precision medicine, reproductive health research, and vaccine development. Member of the National Academy of Engineering (2021) Member of the National Academy of Medicine (2012) Member of the National Academy of Inventors (2015) Top 20 Translational Researchers worldwide (2012 and 2020) Product Design and Best Design of the Year Awards from London Design Museum (2015) Pritzker Award from the Biomedical Engineering Society (2009) Ingber has successfully translated his research into commercial applications, founding 8 companies including Emulate Inc. (Organ Chips), BOA Biomedical Inc., and FreeFlow Medical Devices. His work has led to multiple technologies now in clinical trials or commercial use, including therapeutics for cancer, sepsis treatment devices, and organ chip platforms replacing animal testing. As Founding Director of the Wyss Institute (launched with Harvard's largest-ever philanthropic gift of $125 million), he has created a unique model for translating high-risk research into real-world impact through industry partnerships and startup formation. His laboratory continues to push boundaries in biologically inspired engineering, with current focus areas including advanced organ chip systems, tissue engineering, and the application of mechanical principles to understand and manipulate cellular behavior. The Wyss Institute under his leadership has become a global leader in translating biological design principles into engineering innovations.

Carmelo De MariaView profile

Associate Professor

• Bioengineering
• Biomedical Engineering
• Tissue Engineering
• +5 more

Carmelo De Maria is an Associate Professor in Bioengineering at the Department of Information Engineering, University of Pisa. His research focuses on biofabrication, 3D/4D printing of sustainable biomaterials, and development of advanced medical devices for regenerative medicine. He leads projects in the Enrico Piaggio Research Center, emphasizing applications in tissue engineering, biomedical instrumentation, and low-resource healthcare solutions. Key research areas include: Bioprinting of self-deployable scaffolds for endoluminal tissue regeneration Development of in vitro microphysiological systems for disease modeling Sustainable biomaterials from biomass-derived polymers Open-source medical technologies for global health equity Recent work includes innovations in robotic-based in situ bioprinting, mechanical stimulation of cell cultures, and defect detection in additive manufacturing. His interdisciplinary approach bridges robotics, materials science, and clinical applications to address challenges in musculoskeletal, cardiovascular, and neural tissue engineering. Collaborative projects focus on international cooperation to enhance access to safe, affordable medical technologies in low-resource settings. He actively publishes in high-impact journals and contributes to regulatory frameworks for open-source medical devices.

D. Lansing TaylorView profile

Professor

• Quantitative Systems Pharmacology
• Microphysiological Systems
• Drug Discovery
• +5 more

D. Lansing Taylor serves as Director of the University of Pittsburgh Drug Discovery Institute (UPDDI) and holds the Allegheny Foundation Professorship in Computational and Systems Biology. His leadership integrates academic research with commercial drug development through the UPDDI's technical platforms spanning discovery chemistry, computational biology, and preclinical assessment. Dr. Taylor's educational foundation includes: BS in Zoology from University of Maryland (1968) PhD in Cell Biology from SUNY Albany (1973) Postdoctoral Fellowship in Biophysics at Woods Hole Marine Biology Laboratory (1974) His research pioneers the coupling of Quantitative Systems Pharmacology (QSP) with Microphysiology Systems (MPS) to model disease mechanisms and drug responses. Current work focuses on liver diseases (NAFLD/T2D), cancer metastasis, and neurodegenerative disorders using fluorescent biosensors and spatial analytics. This approach bridges patient-derived cell models with computational prediction of therapeutic outcomes through platforms like BioSystics. Analysis of recent publications reveals three dominant trends: (1) Integration of multi-organ MPS for ADME-Tox and disease modeling, (2) Spatial analytics for cancer recurrence prediction using tissue microdomain networks, and (3) Development of predictive safety assessment platforms combining primary hepatocytes with machine learning. These efforts consistently advance the paradigm of human biomimetic systems for precision medicine. No specific scientific awards or fellowships are detailed in the source text, though his endowed professorship and institute directorship represent significant institutional recognition. Dr. Taylor has mentored numerous researchers through UPDDI's academic-industry collaborations and directed major grant initiatives including the NSF-funded Center for Light Microscope Imaging. His entrepreneurial leadership includes founding three successful biotech companies: Cellomics (acquired by Thermo Fisher), Cellumen (acquired by Cyprotex), and Cernostics (acquired by Castle Biosciences). The UPDDI operates as a comprehensive ecosystem with core facilities in computational chemistry, zebrafish modeling, and preclinical efficacy testing. His current lab work focuses on developing patient digital twin technology through PredxBio and BioSystics, advancing spatial analytics for clinical diagnostics while directing UPDDI's large-scale programs on liver MPS and cancer microenvironments.

Yvon WoappiView profile

Assistant Professor

• Tissue Regeneration
• Systems Bioengineering
• Cellular Heterogeneity
• +12 more

Yvon Woappi is an Assistant Professor in the Department of Physiology and Cellular Biophysics and the Herbert and Florence Irving Assistant Professor of Dermatology at Columbia University's Vagelos College of Physicians and Surgeons. He holds a tertiary appointment in the Department of Biomedical Engineering at the School of Engineering and Applied Science. He leads the Synthetic Regeneration and Systems Physiology Laboratory, focusing on regenerative systems engineering. Woappi's research centers on tissue systems regeneration through a systems bioengineering lens. His lab develops microphysiological wound organoids and synthetic gene engineering tools to decode how diverse skin cells coordinate to restore organ function. Key interests include the interplay between wound healing and neoplasia, and the creation of computational frameworks to model organ-level responses, including immune dynamics. His interdisciplinary work spans physiology, dermatology, and bioengineering. His scientific contributions have been recognized with prestigious awards, including the MIT Rising Star Award and the NIH K99/R00 MOSAIC Prize. These honors reflect his innovative trajectory in regenerative science and biomedical research. Woappi advises a research laboratory focused on synthetic regeneration, where his team integrates experimental models with computational analysis. His lab is supported by competitive grants, including the NIH MOSAIC award, enabling high-impact work in tissue engineering and systems physiology. He is affiliated with Columbia's Health Analytics Center, enhancing cross-disciplinary collaboration.

• Tissue Engineering
• Vascular Biology
• Macrophage Biology
• +3 more

Laura Elise de Heus is a Researcher at the Applied Stem Cell Technologies group within the TechMed Centre at the University of Twente, specializing in advanced tissue engineering models and vascular biology. Her work integrates immunology with micro-engineering to develop physiologically relevant systems for disease modeling. Her primary research interests span Tissue Engineering , Vascular Biology , and Macrophage Biology , with specific focus on organ-on-chip technology and biomaterial development. She investigates how embedded macrophages trigger intravascular coagulation in 3D blood vessel models, addressing critical gaps in understanding vascular inflammation and thrombosis mechanisms. Analysis of her 2019-2024 publications reveals a clear research trajectory: initial work on poly(lactic acid) micro-objects for tissue scaffolding evolved into sophisticated vascular inflammation models incorporating immune cells. This progression demonstrates her contribution to advancing in vitro vascular disease modeling through engineering-immunology integration. Dr. de Heus operates within the Applied Stem Cell Technologies research group at the TechMed Centre, a multidisciplinary institute fostering collaboration between engineering, medicine, and life sciences. Her work exemplifies the center's mission to develop innovative medical technologies through cross-disciplinary approaches.

• Quantitative Biology
• Microphysiological Systems
• Cancer Biology
• +3 more

Iris Luzuriaga Borrajo is a researcher affiliated with the Department of Biochemistry and Genetics at the University of Navarra, Spain. She is part of the Cancer Center Clínica Universidad de Navarra (CCUN) and contributes to the research group focused on Microphysiological Systems and Quantitative Biology. Department: Biochemistry and Genetics Research Group: Microphysiological Systems and Quantitative Biology Clinical Center: Cancer Center Clínica Universidad de Navarra (CCUN) Email: iluzuriagab@unav.es

Thomas HuserView profile

Professor

• Optical Microscopy
• Super-resolution Imaging
• Biophotonics
• +6 more

Thomas Huser is a Professor in the Department of Physics at the University of Bielefeld's Faculty of Physics, with an adjunct professorship in the Department of Internal Medicine at the University of California, Davis. His research group develops advanced optical microscopy techniques for biological applications, focusing on ultra-sensitive imaging of cellular and molecular systems. Physics MA, University of Basel (1992) Physics MS, University of Basel (1994) Physics Ph.D., University of Basel (1998) Postdoc in Materials Science, Lawrence Livermore National Laboratory (1998-2000) Huser's research spans multiple cutting-edge areas in biophotonics, including super-resolution optical microscopy, coherent anti-Stokes Raman spectroscopy (CARS), and nanosensor development. His work bridges physics, biology, and medicine, with applications in HIV research, liver cell imaging, and cancer studies. The group develops novel imaging techniques to study cellular structures at the nanoscale, including virological synapses, tunneling nanotubes, and endothelial fenestrations. His recent publications demonstrate a strong trend toward integrating advanced computational methods with optical microscopy, including deep learning for image reconstruction, novel optical designs using fiber components, and hyperspectral imaging techniques. The research spans fundamental physics of light-matter interactions to direct medical applications in liver disease, HIV transmission, and nanoparticle toxicity. Summa cum laude doctorate from University of Basel Norbert J. Kreidl Award from American Ceramic Society Excellence in Publication Award from LLNL Above and Beyond Teaching Award from Center for Biophotonics Guest Editor for Journal of Biophotonics Editorial roles at Applied Spectroscopy, Scientific Reports, and BME Frontiers Huser leads multiple major research projects funded by the European Union and German Research Foundation, including imaging aging endothelium at the nanoscale, microphysiological sample imaging for polypharmacy evaluation, and sino-German mobility programs for high-speed microscopy. His lab, the Biomolecular Photonics Group, develops innovative imaging technologies while maintaining strong clinical connections through collaborations with medical researchers. The Biomolecular Photonics Group operates state-of-the-art microscopy facilities including super-resolution systems, CARS microscopy, and custom-built imaging platforms. The group maintains international collaborations across Europe and the United States, with particular strengths in translating fundamental optical physics into biomedical applications.

John P. WikswoView profile

Professor

• Biomagnetism
• Systems Biology
• Microfluidics
• +6 more

John P. Wikswo is the University Distinguished Professor at Vanderbilt University, holding appointments in Biomedical Engineering, Molecular Physiology & Biophysics, and Physics. He founded the Vanderbilt Institute for Integrative Biosystems Research and Education (VIIBRE) in 2001, which has become a leader in microfluidic organs-on-chips and systems biology tools. B.A. in Physics, University of Virginia (1970) M.S. and Ph.D. in Physics, Stanford University (1973, 1975) For 47 years, he has pioneered biomagnetic measurements in cardiology, including the first detection of magnetic fields from single axons and cardiac virtual electrode effects. His current work focuses on autonomous robot scientists like Genesis, integrating microfluidics with AI for yeast chemostat studies, and microphysiological systems for drug discovery and toxicology. His 250+ publications and 47 patents span biomedical instrumentation , microfabrication , and interdisciplinary education via the SyBBURE program, which has mentored over 400 students. Awards include the 2017 R&D 100 Award and fellowships in seven societies.

Emily SwindleView profile

Associate Professor

• Mast cells
• Viral-induced respiratory diseases
• Asthma
• +3 more

Dr Emily Swindle is an Associate Professor in Pharmacology at the University of Southampton's Faculty of Medicine. With a PhD in Immunopharmacology from the University of Liverpool (2003), she transitioned from NIH postdoctoral work to establish an interdisciplinary research program focused on mast cell-epithelial interactions in respiratory diseases. PhD in Immunopharmacology (University of Liverpool, 2003) Postdoctoral Fellowship (NIH/NIAID, 2003-2010) Lecturer in Pharmacology (University of Southampton, 2013) Associate Professor in Pharmacology (since 2018) Her research explores three main areas: (1) bronchial epithelial cell-immune cell interactions during rhinovirus infection in asthma, (2) mast cell roles in viral immunity, and (3) lung-on-chip microphysiological systems. These projects integrate primary cell modeling with microfluidic engineering for real-time barrier function analysis. Recent publications highlight her work in membrane lipid dynamics during viral infection (Tissue Barriers 2024), droplet microfluidics for barrier monitoring (RSC Advances 2023), and advanced "airway barrier on chip" systems (European Respiratory Journal 2022). Her team develops models using primary bronchial epithelial cells and mast cells from cord blood. EPSRC-funded lung-on-chip project with Prof Morgan AAIR Charity grants for IL-33/mast cell research Collaborations with engineers and physical scientists GlaxoSmithKline-sponsored clinical trial participation As module lead for the Gastrointestinal (GI) module in the BMBS program and academic coordinator for Prescribing Safety Assessment, she delivers clinical pharmacology teaching while maintaining active PhD examination roles. Her lab's "airway barrier on chip" system employs surface acoustic wave aerosol delivery and droplet-based secretion analysis.

• Tissue Engineering
• 3D Bioprinting
• Regenerative Medicine
• +6 more

Dr. Angela Panoskaltsis-Mortari serves as Professor in both the Department of Medicine and Department of Pediatrics at the University of Minnesota Medical School, with a specialized focus in the Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy. She holds multiple leadership roles including Vice Chair for Research in Pediatrics, Director of the University of Minnesota 3D Bioprinting Facility, Director of the Cytokine Reference Laboratory, and Associate Director of the TL1 Program (CTSI). Her research spans the interdisciplinary field of regenerative medicine with particular emphasis on tissue-organ engineering and biofabrication. The Panoskaltsis-Mortari Laboratory employs two primary approaches: decellularized whole organ scaffolds integrated with sophisticated bioreactors, and advanced 3D bioprinting techniques including extrusion, suspension, and laser-assisted methods. Current projects target the creation of functional lung, trachea, and esophagus tissues for transplantation, as well as developing sophisticated 3D cancer models for evaluating novel drugs and cell therapies. Analysis of her most recent publications reveals a strong dual focus on immunological aspects of transplantation (particularly Graft-versus-Host Disease mechanisms and prevention strategies) alongside cutting-edge biofabrication techniques. Her work bridges fundamental immunology with practical tissue engineering applications, creating translational research pathways from bench to bedside. Dr. Panoskaltsis-Mortari leads or participates in multiple significant research projects including 'Human Organ-on-Chip Platforms for Radiation Exposure Assessment' (2023-2027), 'REVEAL - Research Evaluating Vagal Excitation and Anatomical Linkages' (2022-2025), 'In Vivo Prevention of Murine GVHD' (2022-2027), and 'Sensory Function and Chronic Pain in Cerebral Palsy' (2021-2027), demonstrating her broad research impact across multiple disciplines. Her laboratory accepts students and researchers from diverse backgrounds including biomedical engineering, physiology, stem cell biology, computer science, mechanical engineering, biomaterials science, and surgery, reflecting the highly interdisciplinary nature of her work in regenerative medicine and biofabrication.

• Human Histology
• Embryology
• Tumor Microenvironment
• +3 more

Alessandra Dondero is an Associate Professor at the Department of Experimental Medicine (DIMES) of the University of Genoa, specializing in Human Histology and Embryology. Her research focuses on tumor microenvironment dynamics, NK cell immunobiology, and advanced 3D cancer models for immunotherapy testing. Recent research trends highlight her work in: Developing multi-organ-on-chip systems to study NK cell infiltration Investigating B7-H3 expression in pediatric tumors Engineering hydrogel-based 3D tumor models for in vitro immunotherapy evaluation Elucidating miRNA regulation of NK cell apoptotic pathways Her educational contributions span multiple degree programs in Biotechnology, Medicine, and Radiology, including courses on histology and cytology.

Mathias BusekView profile

Researcher

• Microfluidics
• Organ-on-a-Chip
• Bioprinting
• +3 more

Mathias Busek is a Researcher at the Hybrid Technology Hub within the University of Oslo's Faculty of Medicine. His work focuses on developing advanced microfluidic systems including organ-on-chip technologies, hypoxia modeling platforms, and 3D bioprinting applications. Dr. Busek designs pneumatically actuated microsystems and develops computational models for microfluidic network optimization. His research enables precise control of cellular microenvironments for applications in drug testing and disease modeling. Current projects investigate metabolic crosstalk between organs using pump-less recirculating platforms and develop analytical systems for organoid medium analysis compliant with FDA standards. Busek's publications demonstrate consistent innovation in microengineering approaches for biological applications, with recent advances in 3D-printed tooling for microfluidics and stem cell-derived tissue models. His work bridges engineering precision with biological complexity to create physiologically relevant in vitro systems. Major Scientific Awards: Fraunhofer Institute Award for Innovative Product Development (2017) European EARTO Innovation Award, 3rd Place (2018) Scientia II Fellowship - Marie Curie Co-fund Project (2019) Teaching & Supervision: Conducts practical training in microfluidics and lectures on organ-on-chip technology. No specific student advisees are named in source materials.

• Translational Pharmacology
• 3D Cell Culture Systems
• Microfluidics
• +6 more

Volker M. Lauschke is a Professor in Translational Pharmacology at Karolinska Institutet, Stockholm, Sweden, and Director of the Biofabrication and Tissue Engineering Core Facility. He also serves as Deputy Head of the Margarete Fischer-Bosch Institute of Clinical Pharmacology in Stuttgart, Germany, with guest professorships at Changsha Central South University and Lanzhou University. His research integrates 3D cell culture systems, microfluidics, and genomics to develop therapeutic strategies for NASH, infectious diseases, and metabolic disorders. He has authored over 180 peer-reviewed papers and received awards such as the ISSX Karl Netter Award and Clarivate Highly Cited Researcher recognition. He co-founded HepaPredict and PersoMedix for drug discovery and personalized medicine services. Education: PhD (2013), Masters in Molecular Biosciences (2009), and Bachelors in Molecular and Cellular Biology (2007). Research Interests: Focuses on microphysiological systems, pharmacogenomics, and liver regeneration. Current projects include 3D tissue models for diabetes, NASH, and viral infections, plus bioprinting and drug biasing using BRET biosensors. Awards: ISSX Karl Netter Award (2023), Clarivate Highly Cited (2022), AAPS High Impact (2020), and others.

Dilara PerverView profile

Lecturer

• Hematology
• Biomedical Engineering
• Stem Cell Biology
• +5 more

Dr. Dilara Perver is a Lecturer and Jr. Group Leader at ETH Zürich, affiliated with the Department of Health Sciences and Technology and the Institute of Translational Medicine. She holds a Dr. Sc. ETH Zürich, complemented by M.Sc. degrees in Biology and Chemistry from Hacettepe University (Turkey). Her research focuses on ex-vivo technologies for immuno-cellular therapies targeting hematological malignancies, predictive microphysiological models for leukemia/lymphoma, and development of bioreactors for stem cell expansion. She has authored numerous peer-reviewed articles and book chapters, with a particular emphasis on bone marrow niche engineering and extracellular matrix dynamics. Key professional milestones include a postdoctoral role at ETH Zürich, an internship at Novartis in CAR-T cell therapy development, and leadership roles in academic associations like AVETH and the Scientific Staff Association of Health Sciences and Technology. She has secured grants such as the TÜBİTAK Doctoral Research Grant (USD 120,000) and the National Graduate Student Prestige Scholarship. Her work bridges biomaterials, stem cell biology, and clinical translation, with implications for regenerative medicine and oncology. Dr. Perver is actively involved in teaching and science communication, having completed training in project management, entrepreneurship, and clinical trial design. Her contributions to interdisciplinary research and innovation are further highlighted by her memberships in societies like the International Society for Stem Cell Research (ISSCR) and the European Society for Blood and Marrow Transplantation (EBMT).